The optimal dose of BIBR277 (Telmisartan), the long-acting angiotensin II AT1 receptor antagonist, in patients with mild-to-moderate essential hypertension

Japanese Pharmacology and Therapeutics

Volumn 30, Issue SUPPL. 1, 2002, Pages

  Arakawa, Kikuo ^a   Iimura, Osamo ^a   Abe, Keishi ^a   Saruta, Takao ^a   Yazaki, Yoshio ^a   Ishii, Masao ^a   Ogihara, Toshio ^a   Hiwada, Kunio ^a   Eto, Tanenao ^a   Fukiyama, Koshiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; LONG ACTING DRUG; TELMISARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPTIMAL DRUG DOSE;

EID: 0036031284     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Schmid J, et al. In vivo and in vitro biotransformation of Telmisartan. 1st Int Symp on Angiotensin II Antagonism, London 1997; p. 13.
2. Ebner T, et al. In vitro glucuronidation of Telmisartan, a novel angiotensin II receptor antagonist. 2nd Int Symp on Angiotensinn II Antagonism, London, 1999; p. 44.
3. Takanashi K, et al. CYP2C9 IIe359 and Leu359 variants: Enzyme kinetic study with seven substrates. Pharmacogenetics, 2000; 10: 95-104.
4. Taavitsainen P, et al. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur J Pharmacol 2000; 56: 135-40.
5. Mc Clellan KJ, et al. Candesartan cilexetil: A review of its use in essential hypertension. Drugs 1998; 56: 847-69.
6. 1) receptor blockers in hypertension. J Hum Hypertens 2000; 14: S73-86.
7. 14C-Telmisartan after a single oral administration to rats. Xenobiot Metabol Dispos 1999; 14: 425-31.
8. 14C] Telmisartan in healthy volunteers. J Clin Pharmacol 2000; 40: 1312-22.
9. van Meel JCA, Hauel N, Entzeroth M, Haigh R, Wienen W Antihypertensive effects of the angiotensin receptor antagonist, BIBR 277, in conscious renal hypertensive and spontaneously hypertensive rats. Br J Pharmacol 1993; 108 (Suppl): 191.
10. Wienen W, et al. Pharmacological characterization of the novel nonpeptide angiotensinII receptor antagonist, BIBR 277. Br J Pharmacol 1993; 110: 245-52.
11. Wienen W, et al. Effects on binding characteristics and renal function of the novel, non-peptide angiotensin II antagonist BIBR 277 in the rat. J Hypertens 1994; 12: 119-28.
12. Boehm M, et al. Angiotensin II receptor blockade in TGR (mREN2) 27: Effects of renin-angiotensin-system gene expression and cardiovascular functions. J Hypertens 1995; 13: 891-9.
13. Jacques CA, et al. Hypotensive effects of the angiotensin II antagonist Telmisartan in conscious chronically-instrumented transgenic rats. Arzneim Forsch Drug Res 1996; 46: 755-9.
14. 1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain. Clin Exp Hypertens 1998; 20: 205-21.
15. Stangier J, et al. Pharmacokinetics of orally and intravenously administered Telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000; 28: 149-67.
16. Stangier J, et al. Inhibitory effect of Telmisartan on the blood pressure response to angiotensin II challenge. J Cardiovasc Pharmacol 2001; 38: 672-85.
17. Lacourciere Y. The incidence of cough: A comparison of lisinopril, placebo and Telmisartan, a novel angiotensin II antagonist. Int J Clin Pract 1999; 53 (2): 99-103.